{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087301","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.943448+00:00","generated_at":"2026-05-31T10:46:21.604582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025","bullets":["FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.","Cash and equivalents $83.3M as of June 30, 2024, expected to fund operations into 2026.","Q2 2024 net loss $9.4M vs $16.0M in Q2 2023; R&D expenses down to $2.8M from $8.6M.","Stuart Duty and Andrew Saik appointed as independent directors to the board.","Phase 3 AFib-RVR trial design ongoing; enrollment planned for first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087301","json":"https://secwatch.observer/filing/0001104659-24-087301.json","markdown":"https://secwatch.observer/filing/0001104659-24-087301.md","text":"https://secwatch.observer/filing/0001104659-24-087301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/0001104659-24-087301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/tm2421158d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:46:21.604582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}